Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EPS (Weighted Average and Diluted) (2019 - 2025)

Aclaris Therapeutics (ACRS) has 7 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.16 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 86.78% year-over-year to -$0.16; the TTM value through Dec 2025 reached -$0.53, up 69.01%, while the annual FY2025 figure was -$0.53, 69.01% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.16 in Q4 2025 per ACRS's latest filing, down from -$0.12 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.02 in Q4 2023 and bottomed at -$1.21 in Q4 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.32, with a median of -$0.31 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 95.12% in 2023, then tumbled 5950.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.34 in 2021, then decreased by 20.59% to -$0.41 in 2022, then soared by 95.12% to -$0.02 in 2023, then crashed by 5950.0% to -$1.21 in 2024, then skyrocketed by 86.78% to -$0.16 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.16 in Q4 2025, -$0.12 in Q3 2025, and -$0.13 in Q2 2025.